NASDAQ:ELEV Elevation Oncology (ELEV) Stock Price, News & Analysis $2.93 +0.04 (+1.38%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.86▼$3.0550-Day Range$2.35▼$4.0752-Week Range$0.36▼$5.83Volume192,685 shsAverage Volume1.81 million shsMarket Capitalization$160.09 millionP/E RatioN/ADividend YieldN/APrice Target$7.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Elevation Oncology alerts: Email Address Elevation Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside166.2% Upside$7.80 Price TargetShort InterestBearish14.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.92) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 starsMedical Sector780th out of 936 stocksBiological Products, Except Diagnostic Industry133rd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingElevation Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageElevation Oncology has only been the subject of 4 research reports in the past 90 days.Read more about Elevation Oncology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.89% of the float of Elevation Oncology has been sold short.Short Interest Ratio / Days to CoverElevation Oncology has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Elevation Oncology has recently increased by 28.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldElevation Oncology does not currently pay a dividend.Dividend GrowthElevation Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELEV. Previous Next 2.5 News and Social Media Coverage News SentimentElevation Oncology has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Elevation Oncology this week, compared to 1 article on an average week.Search Interest9 people have searched for ELEV on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Elevation Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Elevation Oncology is held by insiders.Percentage Held by Institutions83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Elevation Oncology's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Elevation Oncology are expected to decrease in the coming year, from ($0.92) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elevation Oncology is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elevation Oncology is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElevation Oncology has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Elevation Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Elevation Oncology Stock (NASDAQ:ELEV)Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Read More ELEV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELEV Stock News HeadlinesJuly 24 at 2:13 PM | uk.finance.yahoo.comQ2 2024 Medpace Holdings Inc Earnings CallJuly 24 at 2:13 PM | seekingalpha.comMedpace Holdings, Inc. (MEDP) Q2 2024 Earnings Call TranscriptJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 27, 2024 | prnewswire.comElevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction CancerMay 14, 2024 | msn.comStephens & Co. Initiates Coverage of Elevation Oncology (ELEV) with Overweight RecommendationMay 7, 2024 | prnewswire.comElevation Oncology to Present at the Citizens JMP Life Sciences ConferenceMay 4, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)May 2, 2024 | markets.businessinsider.comHint Health Announces 8th Annual Hint Summit, the Leading DPC Innovation ConferenceJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 2, 2024 | msn.comElevation Oncology GAAP EPS of -$0.23May 2, 2024 | marketwatch.comElevation Oncology Shares Swing to 5% Gain After Extending Cash RunwayMay 2, 2024 | msn.comELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024May 2, 2024 | prnewswire.comElevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsApril 26, 2024 | finance.yahoo.comClariane: First Quarter 2024 RevenueApril 22, 2024 | seekingalpha.comElevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)April 10, 2024 | msn.comBiologic drug-device combination immunotherapy for metastatic prostate cancer patientsApril 9, 2024 | markets.businessinsider.comPromising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation OncologyApril 8, 2024 | finance.yahoo.comElevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024See More Headlines Receive ELEV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ELEV CUSIPN/A CIK1783032 Webwww.elevationoncology.com Phone716-371-1125FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$7.80 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+166.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.35% Return on Assets-38.54% Debt Debt-to-Equity Ratio0.41 Current Ratio46.22 Quick Ratio46.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book2.27Miscellaneous Outstanding Shares54,640,000Free Float50,212,000Market Cap$160.10 million OptionableOptionable Beta1.39 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Joseph J. Ferra Jr. (Age 49)CEO, President & Director Comp: $897.28kDr. David Dornan Ph.D. (Age 46)Chief Scientific Officer Comp: $620.92kMs. Valerie Malyvanh Jansen M.D. (Age 46)Ph.D., Chief Medical Officer Comp: $685.94kMs. Tammy Furlong CPA (Age 53)P.M.P., CFO & Secretary Mr. Ryan BloomerHead of Tech OpsCandice MasseSenior Director of Corporate Communications & Investor RelationsMr. Robert C. YangVice President of Legal AffairsMr. Biren ShahSenior Vice President of Business & Corporate DevelopmentMore ExecutivesKey CompetitorsStrongbridge BiopharmaNASDAQ:SBBPRain OncologyNASDAQ:RAINMiNK TherapeuticsNASDAQ:INKTBolt BiotherapeuticsNASDAQ:BOLTAVEO PharmaceuticalsNASDAQ:AVEOView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 153,586 shares on 7/26/2024Ownership: 0.281%Farallon Capital Management LLCBought 3,886,663 shares on 5/24/2024Ownership: 7.113%Artal Group S.A.Bought 1,513,015 shares on 5/17/2024Ownership: 2.769%Ikarian Capital LLCSold 1,023,850 shares on 5/17/2024Ownership: 0.271%venBio Partners LLCSold 218,122 shares on 5/15/2024Ownership: 4.934%View All Institutional Transactions ELEV Stock Analysis - Frequently Asked Questions How have ELEV shares performed this year? Elevation Oncology's stock was trading at $0.5370 at the start of the year. Since then, ELEV shares have increased by 445.6% and is now trading at $2.93. View the best growth stocks for 2024 here. How were Elevation Oncology's earnings last quarter? Elevation Oncology, Inc. (NASDAQ:ELEV) released its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. When did Elevation Oncology IPO? Elevation Oncology (ELEV) raised $1 billion in an initial public offering on Friday, June 25th 2021. The company issued 63,000,000 shares at a price of $15.00-$17.00 per share. Who are Elevation Oncology's major shareholders? Elevation Oncology's top institutional investors include Bank of New York Mellon Corp (0.28%). View institutional ownership trends. How do I buy shares of Elevation Oncology? Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELEV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
